Company Performance Metrics
NTpharma provides GMP production of nanovaccines and biopharmaceuticals containing carbohydrate binders.
The project provides for building a facility for production of vaccines and pharmaceuticals in the municipal area of Pereslavl’-Zalessky, 150 kilometers (85 miles) northeast of Moscow.
The project aims at production of new generation vaccines,
including a polyvalent human flu vaccine, and pharmaceuticals for detoxification in oncological therapy and for treatment of amyotrophic lateral sclerosis (ALS/Lou Gehrig’s disease).
NTpharma’s technology allows to reduce by half the time required for culturing and production of the vaccine. This advantage is vital when dealing with vaccines for pandemic flu strains spreading rapidly all over the world.
